Filing Details
- Accession Number:
- 0001181431-14-039927
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-31 17:04:43
- Reporting Period:
- 2014-12-29
- Filing Date:
- 2014-12-31
- Accepted Time:
- 2014-12-31 17:04:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1497253 | Organovo Holdings Inc. | ONVO | Biological Products, (No Disgnostic Substances) (2836) | 271488943 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1549671 | Eric David | 6275 Nancy Ridge Drive, Suite 110 San Diego CA 92121 | Chief Strategy Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-12-29 | 3,700 | $7.50 | 697,706 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-12-30 | 16,300 | $7.56 | 681,306 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $7.50 to $7.52. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $7.50 to $7.6250. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- This number does not include 840,000 shares of common stock underlying outstanding options held by Mr. David; post-transaction Mr. David continues to beneficially own or have a right to acquire 1,521,306 shares of common stock.